These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 16949622)

  • 1. CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity.
    Siuciak JA; Chapin DS; McCarthy SA; Guanowsky V; Brown J; Chiang P; Marala R; Patterson T; Seymour PA; Swick A; Iredale PA
    Neuropharmacology; 2007 Feb; 52(2):279-90. PubMed ID: 16949622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
    Gardell LR; Vanover KE; Pounds L; Johnson RW; Barido R; Anderson GT; Veinbergs I; Dyssegaard A; Brunmark P; Tabatabaei A; Davis RE; Brann MR; Hacksell U; Bonhaus DW
    J Pharmacol Exp Ther; 2007 Aug; 322(2):862-70. PubMed ID: 17519387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT(1A) agonist actions. II. Preclinical behavioral effects.
    Corbin AE; Meltzer LT; Ninteman FW; Wiley JN; Christoffersen CL; Wustrow DJ; Wise LD; Pugsley TA; Heffner TG
    Neuropharmacology; 2000 Apr; 39(7):1211-21. PubMed ID: 10760363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity.
    Marquis KL; Sabb AL; Logue SF; Brennan JA; Piesla MJ; Comery TA; Grauer SM; Ashby CR; Nguyen HQ; Dawson LA; Barrett JE; Stack G; Meltzer HY; Harrison BL; Rosenzweig-Lipson S
    J Pharmacol Exp Ther; 2007 Jan; 320(1):486-96. PubMed ID: 17038512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.
    Depoortère R; Bardin L; Auclair AL; Kleven MS; Prinssen E; Colpaert F; Vacher B; Newman-Tancredi A
    Br J Pharmacol; 2007 May; 151(2):253-65. PubMed ID: 17375086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ST2472: a new potential antipsychotic with very low liability to induce side-effects.
    Stasi MA; Di Serio S; Vertechy M; Schiavone A; Ghirardi O; Minetti P; Campiani G; Borsini F; Carminati P
    Int J Neuropsychopharmacol; 2008 May; 11(3):309-19. PubMed ID: 17925059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme.
    Siuciak JA; Chapin DS; McCarthy SA; Martin AN
    Psychopharmacology (Berl); 2007 Jun; 192(3):415-24. PubMed ID: 17333137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics.
    Grauer SM; Graf R; Navarra R; Sung A; Logue SF; Stack G; Huselton C; Liu Z; Comery TA; Marquis KL; Rosenzweig-Lipson S
    Psychopharmacology (Berl); 2009 May; 204(1):37-48. PubMed ID: 19107466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
    Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
    Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel aminotetralin-type serotonin (5-HT) 2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses.
    Canal CE; Morgan D; Felsing D; Kondabolu K; Rowland NE; Robertson KL; Sakhuja R; Booth RG
    J Pharmacol Exp Ther; 2014 May; 349(2):310-8. PubMed ID: 24563531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.
    McCreary AC; Glennon JC; Ashby CR; Meltzer HY; Li Z; Reinders JH; Hesselink MB; Long SK; Herremans AH; van Stuivenberg H; Feenstra RW; Kruse CG
    Neuropsychopharmacology; 2007 Jan; 32(1):78-94. PubMed ID: 16710314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.
    McFarland K; Price DL; Bonhaus DW
    Behav Pharmacol; 2011 Oct; 22(7):681-92. PubMed ID: 21921840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies.
    Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
    Neuropsychopharmacology; 2007 Jul; 32(7):1540-9. PubMed ID: 17164815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: involvement of the cholinergic muscarinic receptor.
    Wadenberg ML; Fjällström AK; Federley M; Persson P; Stenqvist P
    Int J Neuropsychopharmacol; 2011 Jun; 14(5):644-54. PubMed ID: 20701827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral administration of group III mGlu receptor agonist ACPT-I exerts potential antipsychotic effects in rodents.
    Pałucha-Poniewiera A; Kłodzińska A; Stachowicz K; Tokarski K; Hess G; Schann S; Frauli M; Neuville P; Pilc A
    Neuropharmacology; 2008 Sep; 55(4):517-24. PubMed ID: 18619473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity.
    Ishibashi T; Horisawa T; Tokuda K; Ishiyama T; Ogasa M; Tagashira R; Matsumoto K; Nishikawa H; Ueda Y; Toma S; Oki H; Tanno N; Saji I; Ito A; Ohno Y; Nakamura M
    J Pharmacol Exp Ther; 2010 Jul; 334(1):171-81. PubMed ID: 20404009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Egis-11150: a candidate antipsychotic compound with procognitive efficacy in rodents.
    Gacsályi I; Nagy K; Pallagi K; Lévay G; Hársing LG; Móricz K; Kertész S; Varga P; Haller J; Gigler G; Szénási G; Barkóczy J; Bíró J; Spedding M; Antoni FA
    Neuropharmacology; 2013 Jan; 64():254-63. PubMed ID: 22824189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator.
    Maeda K; Lerdrup L; Sugino H; Akazawa H; Amada N; McQuade RD; Stensbøl TB; Bundgaard C; Arnt J; Kikuchi T
    J Pharmacol Exp Ther; 2014 Sep; 350(3):605-14. PubMed ID: 24947464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity.
    Depoortere R; Boulay D; Perrault G; Bergis O; Decobert M; Françon D; Jung M; Simiand J; Soubrié P; Scatton B
    Neuropsychopharmacology; 2003 Nov; 28(11):1889-902. PubMed ID: 12902993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.